Qingchun Jin

Featured in: Favicon

Articles

Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer | npj Breast Cancer

Apr 15, 2024 | nature.com | Qingchun Jin |Ann H. Partridge |Brittany L. Bychkovsky |Giuseppe Curigliano |Nabihah Tayob |Sara M. Tolaney

AbstractFollowing the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast cancer after chemotherapy. However, optimal identification of high-risk patients who may derive benefit from this genomically-directed therapy is debated.
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial | Nature Communications

Mar 19, 2024 | nature.com | Ann H. Partridge |Beth Overmoyer |Nabihah Tayob |Sara M. Tolaney |Qingchun Jin |Alyssa Pereslete | +1 more

AbstractThe landscape of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) resistance is still being elucidated and the optimal subsequent therapy to overcome resistance remains uncertain. Here we present the final results of a phase Ib/IIa, open-label trial (NCT02871791) of exemestane plus everolimus and palbociclib for CDK4/6i-resistant metastatic breast cancer.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.